Our above data indicated that OVX and ADX exerted their actions on regulating the AT remodeling and resultant metabolic disorders, likely by principally potentiating the Pparg signaling and inactivating the Nr3c1 signaling, respectively. Here, FDX1 is linked to metabolic disease.